Literature DB >> 1969449

Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation.

C S Via1, G C Tsokos, N I Stocks, M Clerici, G M Shearer.   

Abstract

In our study, we have measured in vitro proliferation and IL-2 production by human PBL to characterize the interactions between Th cells and accessory cells (AC) involved in responses to either conventional Ag or alloantigens. IL-2 production and proliferative responses to conventional Ag, such as influenza or tetanus, are exclusively dependent on the presence of CD4+ T cells and AC. In contrast, IL-2 and proliferative responses to alloantigen can be mediated by either CD4+ or CD8+ T cells. CD4+ T cells respond to alloantigen using either autologous AC (self-restricted), or allogeneic AC (allo-restricted), whereas CD8+ T cells respond to alloantigen using allogeneic AC only. The understanding of Th cell-AC interactions involved in in vitro allogeneic responses will be important for delineating the Th cell-AC interactions involved in transplantation immunity as well as in clinical disorders characterized by T cell dysfunction such as human immunodeficiency virus infection and systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969449

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.

Authors:  M Clerici; F T Hakim; D J Venzon; S Blatt; C W Hendrix; T A Wynn; G M Shearer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

2.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

3.  Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection. Gradual decline of both naive and memory alloreactive T cells.

Authors:  L Meyaard; S A Otto; B Hooibrink; F Miedema
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

4.  Various membrane proteins of Francisella tularensis induce interferon-gamma production in both CD4+ and CD8+ T cells of primed humans.

Authors:  A Sjöstedt; M Eriksson; G Sandström; A Tärnvik
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

6.  T cell differentiation and generation of the antigen-specific T cell repertoire in man: observations in MHC class II deficiency.

Authors:  J W Mannhalter; H M Wolf; I Hauber; M Miricka; H Gadner; M M Eibl
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

7.  The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation.

Authors:  R A Puliaev; I A Puliaeva; A E Ryan; C S Via
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2005-12-01

8.  T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity.

Authors:  B L Bermas; M Petri; D Goldman; B Mittleman; M W Miller; N I Stocks; C S Via; G M Shearer
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

9.  Production of type-1 and type-2 cytokines by peripheral blood mononuclear cells of psoriatic patients.

Authors:  N Mozzanica; A Cattaneo; D Trabattoni; A F Finzi; E Schmitt; E Ferrario; M Clerici; G Vignati; M L Villa
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

10.  Human cellular immune response to Giardia lamblia.

Authors:  B Gottstein; N I Stocks; G M Shearer; T E Nash
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.